Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

about

Glucose Metabolism in Cancer and Ischemia: Possible Therapeutic Consequences of the Warburg Effect.

P2860

Q47996619-7207AB40-3FE7-4CC9-8E08-FABCF6E1C94A

P2860

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

Item

http://www.wikidata.org/entity/Q39360754

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

@en

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

@nl

type

Item

label

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

@en

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

@nl

prefLabel

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

@en

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

@nl

P1476

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

@en

P2093

A Tanju Ozcelikay

http://www.w3.org/2001/XMLSchema#string

Arzu Onay-Besikci

http://www.w3.org/2001/XMLSchema#string

Elif Suzmecelik

http://www.w3.org/2001/XMLSchema#string

P2860

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).

Effect of carvedilol on survival in severe chronic heart failure.

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.

Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Beta-blocker benefit according to severity of heart failure.

Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

P304

1087-1093

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1139/Y2012-015

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224823369

http://www.w3.org/2001/XMLSchema#string

P698

22524679

http://www.w3.org/2001/XMLSchema#string

P921

fatty acid

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

about

P2860

P2860

Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921